Delving into the Latest Updates on RetinaPharma Technologies, Inc. with Synapse

Overview

A review on the use of PhotoTarget angiog. (PTA) and PhotoTarget occlusion (PTO) technol. in the treatment of age-related macular degeneration.PTA and PTO rely on a well-defined heating mechanism to release the content of the thermally-labile liposomes and ensure a robust and simple way of targeting specific tissue within the treated organ.They allow greater refinement of treatment areas and therefore markedly reduce the damage to surrounding tissue in relation to traditional procedures.The approach is particularly effective at increasing the range of photosensitizers available, and thus allows greater control over individual treatments.

100 Deals associated with RetinaPharma Technologies, Inc.

Login to view more data

100 Translational Medicine associated with RetinaPharma Technologies, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data